The clinical trial to study a new drug, AP-2.

2025-524480-21-00 · tracked via the Priya Life Science EU tracker

Sponsor

Molefy Pharma S.L.

Sponsor type

Pharmaceutical company

Therapeutic area

Nervous System Diseases

Decision date

10/03/2026

Enrollment target

Sites

Spain

Condition studied

ALS and related disorders like frontotemporal dementia and Alexander disease.

Eligibility

Age group

18-64 years

Sex

Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524480-21-00 on CTIS ↗ ← All trials in the EU